GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

London, 20 November 2025 — GSK plc (LON:GSK, NYSE:GSK) finished Thursday’s session slightly higher, as upbeat broker commentary and a string of recent R&D announcements helped support the pharma giant’s share price against a volatile FTSE 100 backdrop.

Key takeaways for GSK shareholders today

Closing price: GSK shares closed around 1,776p in London (bid 1,776.0p, offer 1,776.5p), up 4.0p (+0.23%) on the day. ^[1]
Intraday range: The stock traded between roughly 1,772p and 1,790p after opening at 1,778p, on volume just over 514,000 shares. ^[2]
Analyst move today:Jefferies reiterated its “Buy” rating and raised its target price from 2,000p to 2,100p, implying around 18% upside from current levels. ^[3]
Strategic news driving sentiment: Investors are still digesting GSK’s new oncology collaboration with LTZ Therapeutics, a £45m AI-powered antimicrobial resistance initiative with the Fleming Initiative, and a treasury share transfer and ongoing buybacks. ^[4]
Medium‑term performance: Over the past year, GSK shares are up roughly 36%, comfortably ahead of many large‑cap peers, with a forward dividend yield around 3.4% and a trailing P/E of about 11x. ^[5]

GSK share price today: how LON:GSK traded on 20 November 2025

Based on end‑of‑day data from Hargreaves Lansdown, GSK closed the London session at around 1,776p, a gain of about 0.23% versus Wednesday’s close of 1,772.5p. The stock opened at 1,778p, touched an intraday high near 1,790.3p, and briefly dipped to about 1,772p before settling in the mid‑1,770s. ^[6]

Trading volume was relatively light at roughly 514,000 shares, compared with multi‑million volumes seen around the late‑October Q3 results. That pattern suggests today’s move was more about steady accumulation than an aggressive re‑rating.

On a 12‑month view, GSK remains near the top end of its trading range: the stock’s 52‑week high stands at 1,830p, versus a low of 1,242.5p, highlighting how strongly the shares have recovered since last year’s trough. ^[7]

FTSE 100 backdrop: calmer macro winds help defensives

Today’s modest rise in GSK came as the FTSE 100 snapped a five‑session losing streak, climbing a little over 0.5% and trading just below the 9,600 level by late session. The rebound was led by Halma and Games Workshop, both hitting record highs after strong updates, while a global “relief rally” following Nvidia’s earnings supported risk appetite. TechStock²

Fresh UK inflation data also helped: the Consumer Prices Index eased to 3.6% year‑on‑year in October, down from 3.8% in September, reinforcing expectations that the Bank of England could cut rates again in December. Lower inflation and the prospect of cheaper borrowing costs are generally supportive for high‑quality, income‑paying defensives like big pharma. TechStock²

In that context, GSK’s gentle move higher today looks consistent with its role as a core defensive holding in the FTSE 100: not the star of the session, but a name investors are comfortable edging back into as macro nerves cool.

Today’s standout GSK news: Jefferies hikes its target price

The most explicitly GSK‑specific headline dated 20 November 2025 came from broker Jefferies. According to GuruWatch, the bank: ^[8]

Reiterated a “Buy” recommendation on GSK
Raised its target price from 2,000p to 2,100p
Issued the call at 05:43 on Thursday
Flagged an implied potential return of roughly 17–18% from the reference price used in the note

The report frames GSK as a still‑attractive value and growth blend, even after a strong 12‑month run, and places the shares comfortably above today’s 1,770–1,780p trading range.

While Jefferies is firmly positive, other houses – such as Deutsche Bank, which recently maintained a Hold stance – remain more cautious, underlining that not all analysts see the stock as a one‑way bet. ^[9]

For investors, the Jefferies move matters less as a single price target and more as a signal that recent pipeline deals and earnings upgrades are resonating with at least part of the analyst community.

Pipeline momentum: LTZ oncology deal still front of mind

Even though the formal announcement landed yesterday (19 November), the market is still processing GSK’s new oncology tie‑up with LTZ Therapeutics, and that story remained highly relevant for trading today. ^[10]

From the official press release and specialist coverage:

GSK has struck a strategic research collaboration with LTZ, an immunotherapy‑focused biotech based in California.
The partners plan to develop up to four potential first‑in‑class myeloid cell engagers (MCEs) for haematologic cancers and solid tumours. ^[11]
GSK is paying $50 million upfront and has committed to further preclinical, clinical and commercial milestone payments (undisclosed). ^[12]
GSK also gains an exclusive option to license worldwide rights to the resulting therapies. ^[13]

MCEs are an emerging class of bispecific immuno‑oncology drugs that direct myeloid cells – a major class of tissue‑resident immune cells – to recognise and kill tumour cells. They promise a novel way to engage the immune system with a potentially more manageable safety profile than some T‑cell‑engaging approaches.

Strategically, the LTZ deal:

Strengthens GSK’s early‑stage oncology pipeline, alongside previous agreements such as its prostate cancer ADC pact with Syndivia. ^[14]
Puts GSK into a competitive field alongside Pfizer, Sanofi, Novartis and Eli Lilly, all of whom have moved into similar myeloid‑engager technologies. ^[15]

For the share price, the deal helps reinforce the idea that GSK is not just a vaccines and HIV story, but is actively building a next‑generation oncology franchise – a key consideration for long‑term valuation.

AI and antimicrobial resistance: the AMR “Grand Challenges”

Another recent announcement that investors are weighing up this week is GSK’s 18 November press release on antimicrobial resistance (AMR). In partnership with the Fleming Initiative at Imperial College London, GSK is: ^[16]

Committing £45 million to fund six new “Grand Challenge” research programmes
Using advanced AI and machine‑learning models to accelerate the discovery of new antibiotics and anti‑fungal drugs
Targeting WHO priority pathogens, including Gram‑negative bacteria and Staphylococcus aureus (including MRSA), as well as serious fungal infections such as Aspergillus
Funding around 50 dedicated UK scientific and academic roles focused entirely on AMR research

The initiative arrives against a backdrop of WHO data showing a worsening global AMR burden and projections of a sharp rise in deaths linked to drug‑resistant infections by 2050. ^[17]

While AMR projects are unlikely to move GSK’s earnings needle in the near term, they:

Reinforce the group’s scientific credibility and leadership in infectious disease
Support the company’s ESG narrative – something many institutional investors increasingly factor into valuations
Build a long‑term pipeline option in an area where relatively few large pharmas remain active

For shareholders, it’s another signal that GSK is leaning into high‑impact science, rather than merely defending legacy franchises.

Capital returns: treasury share transfer and buybacks

Alongside pipeline news, GSK has also been active on the capital‑markets side, with two developments particularly relevant to equity investors this week.

Transfer of treasury shares to employee trust

A Form 6‑K filed on 19 November details how, on 18 November 2025, GSK transferred 22,000,000 ordinary shares from treasury into the GlaxoSmithKline Employee Trust. These shares will be used to satisfy awards under the company’s bonus, performance share and share value plans. ^[18]

Key points from the filing:

The trustee paid £17.995 per share, funded by a loan from a GSK subsidiary
After the transfer, GSK holds 234,819,844 shares in treasury
Total voting rights in issue (excluding treasury) stand at 4,080,611,266, with treasury shares representing 5.75% of voting rights ^[19]

For investors, this move is administrative rather than dilutive: it reallocates shares already in treasury into an employee trust, while clarifying the denominator used for major shareholding disclosures.

Ongoing share repurchases

Separate “Transaction in Own Shares” regulatory announcements show that GSK has continued repurchasing its own stock on the market, including on 18 November, with shares bought across multiple venues (LSE, BATS, Chi‑X) typically around 1,780–1,803p. ^[20]

Buybacks at these levels effectively:

Provide a floor of demand for the shares
Incrementally enhance EPS over time
Signal management’s view that the stock remains attractively valued versus its long‑term prospects

Taken together, the employee‑trust transfer and continued buybacks underline that capital returns remain a priority, alongside GSK’s regular dividend.

How strong is GSK’s recent share price performance?

Hargreaves Lansdown’s performance snapshot (based on previous closes) underlines just how far GSK has run in the last year: ^[21]

1 week: +2.8%
1 month: +9.1%
3 months: +22.1%
6 months: +26.9%
1 year: +36.0%

That rally has been driven by a combination of earnings upgrades and de‑risking around the pipeline and litigation backdrop. On 29 October, Reuters reported that GSK raised its 2025 sales and earnings guidance after strong Q3 growth in HIV and cancer drugs, sending the shares up nearly 7% in a single day to their highest level since May 2024. ^[22]

Despite the run‑up, valuation remains relatively restrained:

Trailing P/E: about 11x
Dividend yield: roughly 3.4%
Market cap: around £71.8 billion ^[23]

For many investors, that combination – mid‑single‑digit yield, modest earnings multiple, and visible growth drivers – helps justify continued interest, especially in a world where bond yields look set to drift lower if central banks keep cutting rates.

What today’s move could mean for investors

Putting it all together, GSK’s modest gain on 20 November 2025 reflects a steady‑as‑she‑goes day rather than a major re‑rating, but several themes stand out:

Analyst sentiment is tilting more positive. Jefferies’ higher 2,100p target suggests that at least one major broker sees scope for further upside, even near the top of the stock’s 12‑month range. ^[24]
Pipeline optionality is improving. The LTZ oncology collaboration and AMR “Grand Challenges” expand GSK’s option set for long‑term growth, particularly in cancer and infectious disease, two areas where payers still support premium pricing for strong data. ^[25]
Capital allocation remains shareholder‑friendly. Ongoing buybacks, a solid dividend and transparent use of treasury shares for employee plans all point to a management team that’s balancing reinvestment with returns. ^[26]
Macro conditions are becoming a tailwind, not a headwind. Cooling UK inflation and the prospect of additional rate cuts provide a supportive backdrop for defensive, cash‑generative names like GSK, even as cyclical sectors enjoy the immediate bounce. TechStock²

None of this guarantees future gains, of course. Clinical setbacks, pricing pressure, or adverse legal developments could still upset the story. But as of 20 November 2025, the overall picture is of a FTSE 100 stalwart that has regained investor confidence, continues to invest aggressively in science, and now enjoys growing support from at least some analysts.

Important reminder

This article is for information only and does not constitute investment advice or a recommendation to buy or sell any security. Share prices can go down as well as up, and you should do your own research or consult a regulated financial adviser before making investment decisions.